To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will examine the effects of formulation on the relative bioavailability of
SB-751689 (400 mg) administered to healthy postmenopausal women. Subjects will receive a
single oral dose of each formulation, with five formulations of SB-751689 tested in total.
Blood samples will be taken up to 24 hours postdose after each dose administration. This
study will provide information for future possible formulation development of SB-751689 for
Phase III.